{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:20:11Z","timestamp":1784841611442,"version":"3.55.0"},"reference-count":103,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,3,1]]},"abstract":"<jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to: Describe the autoimmune pathogenesis of paraneoplastic neurological syndromes.Explain the clinical value of paraneoplastic antibody detection.Describe the general treatment approach to paraneoplastic neurological syndromes.<\/jats:p>\n                  <jats:p>Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.11-3-292","type":"journal-article","created":{"date-parts":[[2006,3,20]],"date-time":"2006-03-20T22:02:49Z","timestamp":1142892169000},"page":"292-305","source":"Crossref","is-referenced-by-count":127,"title":["Managing Paraneoplastic Neurological Disorders"],"prefix":"10.1093","volume":"11","author":[{"given":"Janet W.","family":"de Beukelaar","sequence":"first","affiliation":[{"name":"Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A. Sillevis","family":"Smitt","sequence":"additional","affiliation":[{"name":"Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,3,1]]},"reference":[{"key":"2021122208182852600_R1","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMra023009","article-title":"Paraneoplastic syndromes involving the nervous system","volume":"349","author":"Darnell","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122208182852600_R2","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/brain\/124.6.1138","article-title":"Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients","volume":"124","author":"Graus","year":"2001","journal-title":"Brain"},{"key":"2021122208182852600_R3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00415-002-0706-4","article-title":"Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis\/sensory neuronopathy","volume":"249","author":"Sillevis Smitt","year":"2002","journal-title":"J Neurol"},{"key":"2021122208182852600_R4","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/brain\/awg133","article-title":"Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients","volume":"126","author":"Shams'ili","year":"2003","journal-title":"Brain"},{"key":"2021122208182852600_R5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1212\/WNL.55.5.713","article-title":"Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies","volume":"55","author":"Rojas","year":"2000","journal-title":"Neurology"},{"key":"2021122208182852600_R6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/jnnp.11.2.73","article-title":"Primary sensory neuropathy with muscular changes associated with carcinoma","volume":"11","author":"Denny-Brown","year":"1948","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122208182852600_R7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1212\/WNL.44.1.140","article-title":"Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis","volume":"44","author":"Jean","year":"1994","journal-title":"Neurology"},{"key":"2021122208182852600_R8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00401-001-0498-0","article-title":"Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis","volume":"103","author":"Bernal","year":"2002","journal-title":"Acta Neuropathol (Berl)"},{"key":"2021122208182852600_R9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0140-6736(93)92485-C","article-title":"Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies","volume":"341","author":"Darnell","year":"1993","journal-title":"Lancet"},{"key":"2021122208182852600_R10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/jnnp.62.3.276","article-title":"Spontaneous neurological improvement in anti-Hu associated encephalomyelitis","volume":"62","author":"Byrne","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122208182852600_R11","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.1997.15.8.2866","article-title":"Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival","volume":"15","author":"Graus","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122208182852600_R12","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1212\/WNL.45.10.1873","article-title":"Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice","volume":"45","author":"Sillevis Smitt","year":"1995","journal-title":"Neurology"},{"key":"2021122208182852600_R13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/1531-8249(199902)45:2<162::AID-ANA5>3.0.CO;2-R","article-title":"Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies","volume":"45","author":"Benyahia","year":"1999","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/1531-8249(200001)47:1<9::AID-ANA5>3.0.CO;2-I","article-title":"Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration","volume":"47","author":"Albert","year":"2000","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0022-510X(99)00163-X","article-title":"Cytotoxic T cells against a peptide of Yo protein in patients with paraneoplastic cerebellar degeneration and anti-Yo antibody","volume":"168","author":"Tanaka","year":"1999","journal-title":"J Neurol Sci"},{"key":"2021122208182852600_R16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/1531-8249(20010201)49:2<146::AID-ANA34>3.0.CO;2-E","article-title":"CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity","volume":"49","author":"Yu","year":"2001","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/01.WNL.0000041495.87539.98","article-title":"Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease","volume":"60","author":"Bernal","year":"2003","journal-title":"Neurology"},{"key":"2021122208182852600_R18","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes","volume":"75","author":"Graus","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122208182852600_R19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.20269","article-title":"Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome","volume":"56","author":"Pittock","year":"2004","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/1531-8249(200007)48:1<105::AID-ANA16>3.0.CO;2-G","article-title":"[18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies","volume":"48","author":"Antoine","year":"2000","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R21","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/brain\/124.11.2223","article-title":"The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders","volume":"124","author":"Rees","year":"2001","journal-title":"Brain"},{"key":"2021122208182852600_R22","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1093\/brain\/awh247","article-title":"FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes","volume":"127","author":"Younes-Mhenni","year":"2004","journal-title":"Brain"},{"key":"2021122208182852600_R23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/jnnp.68.4.479","article-title":"Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methyl-prednisolone","volume":"68","author":"Keime-Guibert","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122208182852600_R24","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/S0140-6736(05)66376-3","article-title":"Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin","volume":"365","author":"Sommer","year":"2005","journal-title":"Lancet"},{"key":"2021122208182852600_R25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM200001063420104","article-title":"Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor","volume":"342","author":"Sillevis Smitt","year":"2000","journal-title":"N Engl J Med"},{"key":"2021122208182852600_R26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1215\/S1152851703000395","article-title":"Immunomodulatory treatment trial for paraneoplastic neurological disorders","volume":"6","author":"Vernino","year":"2004","journal-title":"Neuro-oncol"},{"key":"2021122208182852600_R27","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1212\/WNL.53.8.1719","article-title":"Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor","volume":"53","author":"Keime-Guibert","year":"1999","journal-title":"Neurology"},{"key":"2021122208182852600_R28","first-page":"353","volume-title":"Neurologic Complications of Cancer","author":"Posner","year":"1995"},{"key":"2021122208182852600_R29","volume-title":"Cancer and the Nervous System: The Neurologic Complications of Systemic Malignant Disease","author":"Henson","year":"1982"},{"key":"2021122208182852600_R30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00005792-199203000-00001","article-title":"Anti-Hu\u2013associated paraneoplastic encephalomyelitis\/sensory neuronopathy. A clinical study of 71 patients","volume":"71","author":"Dalmau","year":"1992","journal-title":"Medicine (Baltimore)"},{"key":"2021122208182852600_R31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/WNL.50.3.652","article-title":"Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies","volume":"50","author":"Lucchinetti","year":"1998","journal-title":"Neurology"},{"key":"2021122208182852600_R32","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.4065\/78.11.1363","article-title":"Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis","volume":"78","author":"Lawn","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"2021122208182852600_R33","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/123.7.1481","article-title":"Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients","volume":"123","author":"Gultekin","year":"2000","journal-title":"Brain"},{"key":"2021122208182852600_R34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ana.410390516","article-title":"Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis","volume":"39","author":"Dropcho","year":"1996","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ana.1127","article-title":"ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity","volume":"50","author":"Chan","year":"2001","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/1531-8249(200003)47:3<297::AID-ANA4>3.0.CO;2-4","article-title":"New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity","volume":"47","author":"Vernino","year":"2000","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R37","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/brain\/91.3.481","article-title":"\u201cLimbic encephalitis\u201d and its association with carcinoma","volume":"91","author":"Corsellis","year":"1968","journal-title":"Brain"},{"key":"2021122208182852600_R38","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/brain\/120.6.923","article-title":"Limbic encephalitis and small cell lung cancer. Clinical and immunological features","volume":"120","author":"Alamowitch","year":"1997","journal-title":"Brain"},{"key":"2021122208182852600_R39","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJM199906103402303","article-title":"A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer","volume":"340","author":"Voltz","year":"1999","journal-title":"N Engl J Med"},{"key":"2021122208182852600_R40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1552-6569.2001.tb00011.x","article-title":"Limbic encephalitis investigated by 18FDG-PET and 3D MRI","volume":"11","author":"Kassubek","year":"2001","journal-title":"J Neuroimaging"},{"key":"2021122208182852600_R41","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/brain\/awh203","article-title":"Clinical analysis of anti-Ma2-associated encephalitis","volume":"127","author":"Dalmau","year":"2004","journal-title":"Brain"},{"key":"2021122208182852600_R42","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/brain\/awh077","article-title":"Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis","volume":"127","author":"Vincent","year":"2004","journal-title":"Brain"},{"key":"2021122208182852600_R43","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/ana.10713","article-title":"Voltage-gated potassium channel antibodies in limbic encephalitis","volume":"54","author":"Pozo-Rosich","year":"2003","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/S0317167100000469","article-title":"Reversible paraneoplastic encephalomyelitis associated with a benign ovarian teratoma","volume":"26","author":"Taylor","year":"1999","journal-title":"Can J Neurol Sci"},{"key":"2021122208182852600_R45","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ana.1288","article-title":"Molecular and clinical diversity in paraneoplastic immunity to Ma proteins","volume":"50","author":"Rosenfeld","year":"2001","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R46","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1212\/WNL.42.10.1938","article-title":"Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease","volume":"42","author":"Hammack","year":"1992","journal-title":"Neurology"},{"key":"2021122208182852600_R47","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1017\/S0317167100048629","article-title":"Paraneoplastic cerebellar degeneration","volume":"20","author":"Posner","year":"1993","journal-title":"Can J Neurol Sci"},{"key":"2021122208182852600_R48","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJM199006283222604","article-title":"Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration","volume":"322","author":"Furneaux","year":"1990","journal-title":"N Engl J Med"},{"key":"2021122208182852600_R49","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1073\/pnas.88.8.3451","article-title":"Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration","volume":"88","author":"Fathallah-Shaykh","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122208182852600_R50","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/brain\/120.8.1279","article-title":"Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome","volume":"120","author":"Mason","year":"1997","journal-title":"Brain"},{"key":"2021122208182852600_R51","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1212\/01.WNL.0000113749.77217.01","article-title":"Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer","volume":"62","author":"Bataller","year":"2004","journal-title":"Neurology"},{"key":"2021122208182852600_R52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00415-005-0882-0","article-title":"An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes","volume":"253","author":"Shams'ili","year":"2006","journal-title":"J Neurol"},{"key":"2021122208182852600_R53","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/archneur.1986.00520110055016","article-title":"Opsoclonus in adults. Report of three cases and review of the literature","volume":"43","author":"Digre","year":"1986","journal-title":"Arch Neurol"},{"key":"2021122208182852600_R54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00005792-198803000-00003","article-title":"Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome","volume":"67","author":"Anderson","year":"1988","journal-title":"Medicine (Baltimore)"},{"key":"2021122208182852600_R55","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1007\/s00415-002-0913-z","article-title":"Anti-Ri antibody positive opsoclonus-myoclonus in a male patient with breast carcinoma","volume":"249","author":"Wirtz","year":"2002","journal-title":"J Neurol"},{"key":"2021122208182852600_R56","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/brain\/124.2.437","article-title":"Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus","volume":"124","author":"Bataller","year":"2001","journal-title":"Brain"},{"key":"2021122208182852600_R57","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/1097-0142(20010415)91:8<1423::AID-CNCR1148>3.0.CO;2-F","article-title":"Anti-Ri-associated paraneoplastic opsoclonus-ataxia syndrome in a man with transitional cell carcinoma","volume":"91","author":"Prestigiacomo","year":"2001","journal-title":"Cancer"},{"key":"2021122208182852600_R58","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/1097-0142(197602)37:2<846::AID-CNCR2820370233>3.0.CO;2-L","article-title":"Favorable prognosis for survival in children with coincident opso-myoclonus and neuroblastoma","volume":"37","author":"Altman","year":"1976","journal-title":"Cancer"},{"key":"2021122208182852600_R59","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/mpo.1138","article-title":"Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study","volume":"36","author":"Rudnick","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"2021122208182852600_R60","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ana.410360615","article-title":"Immunological and pathological study of anti-Ri-associated encephalopathy","volume":"36","author":"Hormigo","year":"1994","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R61","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1212\/01.WNL.0000129983.06983.4E","article-title":"Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis","volume":"63","author":"Linke","year":"2004","journal-title":"Neurology"},{"key":"2021122208182852600_R62","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00431-002-0934-8","article-title":"Metaiodobenzylguanidine total-body scintigraphy required for revealing occult neuroblastoma in opsoclonus-myoclonus syndrome","volume":"161","author":"Swart","year":"2002","journal-title":"Eur J Pediatr"},{"key":"2021122208182852600_R63","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1067\/mpd.2001.118200","article-title":"Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies","volume":"139","author":"Hayward","year":"2001","journal-title":"J Pediatr"},{"key":"2021122208182852600_R64","doi-asserted-by":"crossref","first-page":"13254","DOI":"10.1073\/pnas.95.22.13254","article-title":"The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia","volume":"95","author":"Yang","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122208182852600_R65","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1523\/JNEUROSCI.16-03-01114.1996","article-title":"The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies","volume":"16","author":"Buckanovich","year":"1996","journal-title":"J Neurosci"},{"key":"2021122208182852600_R66","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ana.10462","article-title":"Autoantigen diversity in the opsoclonus-myoclonus syndrome","volume":"53","author":"Bataller","year":"2003","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R67","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/1097-0142(19950101)75:1<99::AID-CNCR2820750117>3.0.CO;2-I","article-title":"Major histocompatibility proteins, anti-Hu antibodies and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer","volume":"75","author":"Dalmau","year":"1995","journal-title":"Cancer"},{"key":"2021122208182852600_R68","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00043426-200007000-00007","article-title":"Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus","volume":"22","author":"Antunes","year":"2000","journal-title":"J Pediatr Hematol Oncol"},{"key":"2021122208182852600_R69","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0887-8994(02)00457-5","article-title":"Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia","volume":"27","author":"Pranzatelli","year":"2002","journal-title":"Pediatr Neurol"},{"key":"2021122208182852600_R70","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s004150050270","article-title":"Anti-Ri positive opsoclonus-myoclonus-ataxia in ovarian duct cancer","volume":"245","author":"Jongen","year":"1998","journal-title":"J Neurol"},{"key":"2021122208182852600_R71","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1212\/WNL.43.1_Part_1.207","article-title":"Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus","volume":"43","author":"Dropcho","year":"1993","journal-title":"Neurology"},{"key":"2021122208182852600_R72","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1056\/NEJM199501193320317","article-title":"Improvement of paraneoplastic opsoclonus-myoclonus after protein A column therapy","volume":"332","author":"Nitschke","year":"1995","journal-title":"N Engl J Med"},{"key":"2021122208182852600_R73","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1542\/peds.109.1.86","article-title":"Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae","volume":"109","author":"Mitchell","year":"2002","journal-title":"Pediatrics"},{"key":"2021122208182852600_R74","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/(SICI)1096-911X(199704)28:4<284::AID-MPO7>3.0.CO;2-E","article-title":"Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group","volume":"28","author":"Russo","year":"1997","journal-title":"Med Pediatr Oncol"},{"key":"2021122208182852600_R75","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1017\/S0317167100041974","article-title":"The distinctive clinical features of paraneoplastic sensory neuronopathy","volume":"19","author":"Chalk","year":"1992","journal-title":"Can J Neurol Sci"},{"key":"2021122208182852600_R76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ana.410020103","article-title":"Subacute sensory neuropathy: a remote effect of carcinoma","volume":"2","author":"Horwich","year":"1977","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R77","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1212\/WNL.44.12.2258","article-title":"Indolent anti-Hu-associated paraneoplastic sensory neuropathy","volume":"44","author":"Graus","year":"1994","journal-title":"Neurology"},{"key":"2021122208182852600_R78","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ana.410440620","article-title":"Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy","volume":"44","author":"Molinuevo","year":"1998","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R79","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/1531-8249(20010201)49:2<214::AID-ANA41>3.0.CO;2-W","article-title":"Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy","volume":"49","author":"Antoine","year":"2001","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R80","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/jnnp.61.3.270","article-title":"Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes","volume":"61","author":"Honnorat","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122208182852600_R81","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ana.20529","article-title":"Amphiphysin autoimmunity: Paraneoplastic accompaniments","volume":"58","author":"Pittock","year":"2005","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R82","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/jnnp.66.2.214","article-title":"Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma","volume":"66","author":"Saiz","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122208182852600_R83","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/jnnp.60.4.388","article-title":"Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies","volume":"60","author":"Uchuya","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122208182852600_R84","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/(SICI)1097-4598(199712)20:12<1576::AID-MUS13>3.0.CO;2-Z","article-title":"Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature","volume":"20","author":"OhSJ, Dropcho","year":"1997","journal-title":"Muscle Nerve"},{"key":"2021122208182852600_R85","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/mus.20332","article-title":"Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer","volume":"32","author":"Wirtz","year":"2005","journal-title":"Muscle Nerve"},{"key":"2021122208182852600_R86","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","article-title":"The Lambert-Eaton myasthenic syndrome. A review of 50 cases","volume":"111","author":"O'Neill","year":"1988","journal-title":"Brain"},{"key":"2021122208182852600_R87","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/jnnp.54.9.764","article-title":"Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients","volume":"54","author":"Elrington","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122208182852600_R88","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00415-003-1063-7","article-title":"The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland","volume":"250","author":"Wirtz","year":"2003","journal-title":"J Neurol"},{"key":"2021122208182852600_R89","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ana.410070112","article-title":"The carcinomatous neuromyopathy of oat cell lung cancer","volume":"7","author":"Hawley","year":"1980","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R90","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jneuroim.2004.10.018","article-title":"HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome","volume":"159","author":"Wirtz","year":"2005","journal-title":"J Neuroimmunol"},{"key":"2021122208182852600_R91","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2005.04.001","article-title":"P\/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer","volume":"164","author":"Wirtz","year":"2005","journal-title":"J Neuroimmunol"},{"key":"2021122208182852600_R92","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/jnnp.58.1.85","article-title":"An improved diagnostic assay for Lambert-Eaton myasthenic syndrome","volume":"58","author":"Motomura","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122208182852600_R93","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ana.410330126","article-title":"Cloning and characterization of a Lambert-Eaton myasthenic syndrome antigen","volume":"33","author":"Rosenfeld","year":"1993","journal-title":"Ann Neurol"},{"key":"2021122208182852600_R94","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.40.10.1552","article-title":"Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma","volume":"40","author":"Chalk","year":"1990","journal-title":"Neurology"},{"key":"2021122208182852600_R95","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","article-title":"3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome","volume":"321","author":"McEvoy","year":"1989","journal-title":"N Engl J Med"},{"key":"2021122208182852600_R96","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","article-title":"A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome","volume":"54","author":"Sanders","year":"2000","journal-title":"Neurology"},{"key":"2021122208182852600_R97","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/WNL.34.4.480","article-title":"Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome","volume":"34","author":"Newsom-Davis","year":"1984","journal-title":"Neurology"},{"key":"2021122208182852600_R98","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1212\/WNL.42.7.1422","article-title":"Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy","volume":"42","author":"Bird","year":"1992","journal-title":"Neurology"},{"key":"2021122208182852600_R99","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.7326\/0003-4819-134-12-200106190-00008","article-title":"Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study","volume":"134","author":"Buchbinder","year":"2001","journal-title":"Ann Intern Med"},{"key":"2021122208182852600_R100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"key":"2021122208182852600_R101","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mus.10313","article-title":"Inflammatory myopathies: clinical, diagnostic and therapeutic aspects","volume":"27","author":"Mastaglia","year":"2003","journal-title":"Muscle Nerve"},{"key":"2021122208182852600_R102","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00002281-200011000-00001","article-title":"Update on myositis-specific and myositis-associated autoantibodies","volume":"12","author":"Targoff","year":"2000","journal-title":"Curr Opin Rheumatol"},{"key":"2021122208182852600_R103","first-page":"1","volume-title":"Evaluation and Treatment of Myopathies","author":"Griggs","year":"1995"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.11-3-292","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.11-3-292","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/11\/3\/292\/41850880\/oncolo_11_3_292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/11\/3\/292\/41850880\/oncolo_11_3_292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T13:34:32Z","timestamp":1640180072000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/11\/3\/292\/6398180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,1]]},"references-count":103,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2006,3,1]]},"published-print":{"date-parts":[[2006,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.11-3-292","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,3,1]]},"published":{"date-parts":[[2006,3,1]]}}}